Video

Dr. Opyrchal on the Current State of Biomarkers in TNBC

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Video Player is loading.
Current Time 0:00
Duration 1:24
Loaded: 0%
Stream Type LIVE
Remaining Time 1:24
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Mateusz Opyrchal, MD, PhD, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the current state of biomarkers in triple-negative breast cancer (TNBC).

Identifying actionable biomarkers in breast cancer and other solid malignancies remains an ongoing challenge, Opyrchal says. In TNBC, PD-L1 expression has shown correlation with improved likelihood of response; however, some clinical trials have not corroborated this evidence.

Despite the inconclusive findings from clinical trials, the checkpoint inhibitor atezolizumab (Tecentriq) in combination with nab-paclitaxel (Abraxane) is approved for patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 as determined by an FDA-approved test.

Identifying additional biomarkers that can target chemotherapy-resistant TNBC in the neoadjuvant setting may have a significant effect on how to sensitize patients with immunotherapy in the future, concludes Opyrchal.

Newsletter

Stay up to date on the most recent and practice-changing oncology data